Figure 9.
Schematic illustration of the mechanisms for IL-2/IL-2Ab-afforded protection to the ischemic brain. IL-2/IL-2Ab treatment protects against ischemic brain injury by selectively expanding the number of Tregs in vivo and boosts the immunomodulatory function of Tregs. Elevated expression of CD39/CD73 on Tregs is important for IL-2/IL-2Ab-afforded neuroprotection. Detailed information about statistical analysis for each experiment is summarized in Table 9-1.